BioWorld

June 21, 2004

OSI's Prosidion Buying Diabetes Drug, Assets For At Least $35M

OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today) Read More

With Poor Data, Inflazyme To Drop LSAID In Asthma

FBI: Biotech Industry Not Facing Serious Problem' Of Extremists

After Reagan's Death, Pressure Mounts For Human ESC Reform

Guilford Licenses GPI 1485 To New Company Symphony

Other News To Note

Clarification

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...